Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

被引：3
|
作者：
Kelly, Kevin R. [1 ]
Chanan-Khan, Asher [2 ]
Heffner, Leonard T. [3 ]
Somlo, George [4 ]
Siegel, David S. [5 ]
Zimmerman, Todd [6 ]
Karnad, Anand [7 ]
Munshi, Nikhil C. [8 ]
Jagannath, Sundar [9 ]
Greenberg, Allen L. [10 ]
Lonial, Sagar [3 ]
Roy, Vivek [2 ]
Ailawadhi, Sikander [2 ]
Barmaki-Rad, Farima [11 ]
Chavan, Shailesh [12 ]
Patel, Pankaj [12 ]
Wartenberg-Demand, Andrea [11 ]
Haeder, Thomas [11 ]
Anderson, Kenneth C. [13 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[5] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[6] Univ Chicago Med, Chicago, IL USA
[7] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[8] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[9] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA
[10] Mem Canc Inst, Pembroke Pines, FL USA
[11] Biotest AG, Dreieich, Germany
[12] Biotest Pharmaceut Corp, Boca Raton, FL USA
[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
    P G Richardson
    C C Hofmeister
    N S Raje
    D S Siegel
    S Lonial
    J Laubach
    Y A Efebera
    D H Vesole
    A K Nooka
    J Rosenblatt
    D Doss
    M H Zaki
    A Bensmaine
    J Herring
    Y Li
    L Watkins
    M S Chen
    K C Anderson
    Leukemia, 2017, 31 : 2695 - 2701
  • [32] Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
    Richardson, P. G.
    Hofmeister, C. C.
    Raje, N. S.
    Siegel, D. S.
    Lonial, S.
    Laubach, J.
    Efebera, Y. A.
    Vesole, D. H.
    Nooka, A. K.
    Rosenblatt, J.
    Doss, D.
    Zaki, M. H.
    Bensmaine, A.
    Herring, J.
    Li, Y.
    Watkins, L.
    Chen, M. S.
    Anderson, K. C.
    LEUKEMIA, 2017, 31 (12) : 2695 - 2701
  • [33] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Khouri, Jack
    Faiman, Beth
    Wei, Wei
    Grabowski, Dale
    Samaras, Christy Joy
    Mahfouz, Reda
    Lazarus, Hillard
    Dean, Robert
    Malek, Eshan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Rosko, Nathaniel
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Valent, Jason
    Reu, Frederic
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E262 - E263
  • [35] LENALIDOMIDE 25 MG + LOW-DOSE DEXAMETHASONE: EFFICACY & SAFETY IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MYELOMA
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Zhou, D.
    Ke, X.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Wang, J.
    Zhang, J.
    Mei, J.
    Hou, J.
    HAEMATOLOGICA, 2013, 98 : 603 - 603
  • [36] Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
    Lee, Sung-Eun
    Lim, Ji-Young
    Ryu, Da-Bin
    Kim, Tae Woo
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Min, Chang-Ki
    BLOOD, 2015, 126 (23)
  • [37] Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
    Zagouri, Flora
    Roussou, Maria
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Kanellias, Nikolaos
    Kalapanida, Despoina
    Christoulas, Dimitrios
    Migkou, Magdalini
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1776 - 1780
  • [38] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [39] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
  • [40] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Munshi, Nikhil C.
    Mitsiades, Constantine
    Richardson, Paul G.
    Anderson, Kenneth C.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
12345